Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074008 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT01074008 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 74 participants.
The verdict
NCT01074008, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.
Interventions
- DRUG Ritonavir
- DRUG ABT-072
- DRUG ABT-450
- DRUG ABT-333
- DRUG Peginterferon alpha-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074008
The ClinicalTrials.gov registry entry for NCT01074008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT01074008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01074008 about?
NCT01074008 is a clinical study titled "A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072". This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.
What is the current status of trial NCT01074008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2010-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01074008?
The interventions under investigation include: Ritonavir (DRUG), ABT-072 (DRUG), ABT-450 (DRUG), ABT-333 (DRUG), Peginterferon alpha-2a (DRUG).
Who is sponsoring clinical trial NCT01074008?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.